| Description | Potassium oxonate (Potassium azaorotate) is a uricase inhibitor that prevents metabolism and excretion of uric acid and induces embryotoxicity and nephrotoxicity in rats. |
| In vivo | Potassium oxonate是S-1的成分之一，S-1是一种含有抗肿瘤化合物5-氟尿嘧啶前药的混合物，它能够抑制5-氟尿嘧啶在大鼠中的胃肠道毒性[1]。含有Potassium oxonate的配方已被用于治疗胃癌、胰腺癌、肺癌、头颈癌及乳腺癌[2]。 |
| Synonyms | Oxonic Acid (potassium salt), 氧嗪酸钾, Potassium otastat, Potassium azaorotate |
| molecular weight | 195.17 |
| Molecular formula | C4H2KN3O4 |
| CAS | 2207-75-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: 9.09 mg/mL (46.57 mM), Sonication is recommended. |
| References | 1. Yoshisue K, Masuda H, Matsushima E,et al.Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J].Drug Metab Dispos. 2000 Oct;28(10):1162-7. 2. Chhetri P . Current Development of, Anti-Cancer Drug S-1[J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016. |